🔗 Share this article World Health Organization Sounds Warning Over Critical Scarcity of Obesity Jabs Fewer than a tenth of people that would benefit from weight-loss injections such as Wegovy can access them, caution the WHO as it issues its initial recommendations on the drugs. Considering in excess of 1,000,000,000 people worldwide currently classified as obese, it is advocating for increased and just access to this class of drugs. According to projections, over two billion will be obese by 2030 unless action is taken. "Our latest guidelines affirms that excess weight is a chronic disease that can be addressed with comprehensive and lifelong treatment," remarked its chief Tedros Adhanom Ghebreyesus. High costs, limited production capacity, and logistical bottlenecks are major obstacles to universal access to the injections that can assist patients in reducing considerable body mass, explains the body. Skinny Jab Shortage Even in the current most optimistic outlook, the manufacturing of GLP-1 therapies could only cover approximately 100 million people – under 10% of the global need, per the WHO. The recommendation encourages governments and firms to increase access, via approaches like patent sharing. The intellectual property rights on semaglutide – the core ingredient of the drug Wegovy – is due to expire in several nations in 2026. How Weight-Loss Injections Operate GLP-1 drugs replicate a natural hormone to slow digestion, curb appetite and enhance satiety so people reduce food intake. People usually see weight reduction in the initial weeks of starting on the once-weekly jabs. Studies points to users may regain a significant portion after a year of stopping the medication, when their usual hunger return. Being above a healthy weight elevates your chance for experiencing health problems, including type 2 diabetes, cardiovascular issues, stroke, and certain cancers. Excess weight affects people in every country and was associated with 3.7 million fatalities worldwide in 2024, per the WHO.
Fewer than a tenth of people that would benefit from weight-loss injections such as Wegovy can access them, caution the WHO as it issues its initial recommendations on the drugs. Considering in excess of 1,000,000,000 people worldwide currently classified as obese, it is advocating for increased and just access to this class of drugs. According to projections, over two billion will be obese by 2030 unless action is taken. "Our latest guidelines affirms that excess weight is a chronic disease that can be addressed with comprehensive and lifelong treatment," remarked its chief Tedros Adhanom Ghebreyesus. High costs, limited production capacity, and logistical bottlenecks are major obstacles to universal access to the injections that can assist patients in reducing considerable body mass, explains the body. Skinny Jab Shortage Even in the current most optimistic outlook, the manufacturing of GLP-1 therapies could only cover approximately 100 million people – under 10% of the global need, per the WHO. The recommendation encourages governments and firms to increase access, via approaches like patent sharing. The intellectual property rights on semaglutide – the core ingredient of the drug Wegovy – is due to expire in several nations in 2026. How Weight-Loss Injections Operate GLP-1 drugs replicate a natural hormone to slow digestion, curb appetite and enhance satiety so people reduce food intake. People usually see weight reduction in the initial weeks of starting on the once-weekly jabs. Studies points to users may regain a significant portion after a year of stopping the medication, when their usual hunger return. Being above a healthy weight elevates your chance for experiencing health problems, including type 2 diabetes, cardiovascular issues, stroke, and certain cancers. Excess weight affects people in every country and was associated with 3.7 million fatalities worldwide in 2024, per the WHO.